Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia (BPH)
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
This trial is conducted to evaluate the effect of etonogestrel in comparison to placebo on: the prostate volume and the urinary complaints; the urinary flow and the urinary volume in the bladder after voiding; the progression of…
- Trial name
- NCT00651807
- Testing
- etonogestrel
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- Organon and Co
Benign Prostatic Hyperplasia
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
The purpose of this study is to evaluate the safety and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- PLUS-1 (NCT01966614)
- Testing
- PRX302
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 479 people
- Sponsor
- Sophiris Bio Corp
Prostatic Diseases
Benign Prostatic Hyperplasia in Taiwan
Primary Objective: To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders To compare the sexual…
- Trial name
- NCT00941343
- Testing
- Alfuzosin (XATRAL® - SL770499)
- Where
- Taiwan
- Volunteers
- 362 people
- Sponsor
- Sanofi
BPH
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with…
- Trial name
- NCT00527488
- Testing
- Degarelix
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers
- Trial name
- NCT07103278
- Testing
- AD-116, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Prostatic Hypertrophy, Benign
Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of…
- Trial name
- NCT00461123
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Bayer
Benign Prostatic Hyperplasia
A Pilot Study Of The ALPFA Benign Prostatic Hyperplasia (BPH) Pulsed Field Ablation (PFA) System
The ALPFA Medical BPH Pilot Study is a prospective, open label, single arm pilot study to assess the use of the ALPFA BPH PFA System in the treatment of men over the age of 45 with obstructive urinary symptoms associated with…
- Trial name
- NCT06965582
- Testing
- ALPFA BPH PFA System
- Where
- 4 sites in Czechia, Italy and 1 more
- Volunteers
- 100 people
- Sponsor
- ALPFA Medical
Neoplasms, Prostate, Benign Prostatic Hyperplasia
Economic Analyses of the REDUCE Trial
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial.
- Conditions
- Neoplasms, Prostate, Benign Prostatic Hyperplasia, Cancer
- Trial name
- NCT01337258
- Testing
- Dutasteride
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Adherence and length of treatment with a 5-alpha reductase inhibitor (5ARI) therapy may be associated with improved clinical outcomes for patients with enlarged prostates (EP) and lower health care related costs.
- Trial name
- NCT01376258
- Testing
- 5ARI
- Volunteers
- 28,903 people
- Sponsor
- GlaxoSmithKline
Impotence
Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.
- Trial name
- NCT00143221
- Testing
- Viagra
- Volunteers
- 350 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Benign Prostate Hypertrophy(BPH), Renal Calculi
Stone and Laser Therapies Post-Market Study (SALT)
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g.…
- Conditions
- Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
- Trial name
- SALT (NCT06982235)
- Testing
- Ureteroscope system, Laser system
- Where
- 5 sites in United States
- Volunteers
- 238 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
- Trial name
- NCT00759135
- Testing
- 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
- Where
- 30 sites in United States
- Volunteers
- 85 people
- Sponsor
- Nymox Corporation
Prostatic Hyperplasia
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved…
- Trial name
- NCT02244268
- Testing
- ALNA®
- Volunteers
- 3,629 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Comparing UroLift Experience Against Rezūm
C.L.E.A.R. Study is poised to compare the patient experience post procedure, including catheterization needs as well as retreatment and BPH medication rates following treatment with either the UroLift® System or Rezūm™ System…
- Trial name
- CLEAR (NCT04338776)
- Testing
- UroLift, Rezum
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects
- Trial name
- NCT07444385
- Testing
- AD-116, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperplasia
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.
- Trial name
- NCT01203371
- Testing
- Naftopidil, Tamsulosin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Prostatic Hyperplasia
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
This retrospective study aims to quantify the relationship between 5-alpha-reductase inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention (AUR) or prostate surgery in patients with benign…
- Trial name
- NCT01334723
- Testing
- Adherent with 5-alpha-reductase inhibitor (5ARI) therapy, Non-adherent to 5ARI therapy
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System
To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
- Trial name
- CV (NCT02029560)
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- JW Pharmaceutical
Urinary Retention, Prostatic Hyperplasia
Clinical Trial in Males With BPH (Enlarged Prostate)
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. Free study-related medical care provided.
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00029822
- Testing
- Alfuzosin (SL770499)
- Where
- 54 sites in United States, Australia and 15 more
- Volunteers
- 1,522 people
- Sponsor
- Sanofi